Escherichia coli Infections - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Escherichia coli Infections - Pipeline Review, H1 2018’, provides an overview of the Escherichia coli Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections

- The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects

- The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ABAC Therapeutics SA

Adenium Biotech ApS

AstraZeneca Plc

Atterx Biotherapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Emergent BioSolutions Inc

F. Hoffmann-La ...

ABAC Therapeutics SA

Adenium Biotech ApS

AstraZeneca Plc

Atterx Biotherapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Emergent BioSolutions Inc

F. Hoffmann-La Roche Ltd

Hsiri Therapeutics LLC

Immuron Ltd

Innovation Pharmaceuticals Inc

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Nabriva Therapeutics plc

Navigen Inc

Northern Antibiotics Oy

Nosopharm SAS

Novabiotics Ltd

Oxford Drug Design Ltd

Paratek Pharmaceuticals Inc

Phico Therapeutics Ltd

Protein Potential LLC

PTC Therapeutics Inc

Recce Ltd

Sealife PHARMA GMBH

Syntiron LLC

TCM Biotech International Corp

Tetraphase Pharmaceuticals Inc

Venus Medicine Research Center

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Escherichia coli Infections – Overview 6

Escherichia coli Infections – Therapeutics Development 7

Escherichia coli Infections ...

Table of Contents

Table of Contents 2

Introduction 5

Escherichia coli Infections – Overview 6

Escherichia coli Infections – Therapeutics Development 7

Escherichia coli Infections – Therapeutics Assessment 18

Escherichia coli Infections – Companies Involved in Therapeutics Development 27

Escherichia coli Infections – Drug Profiles 42

Escherichia coli Infections – Dormant Projects 165

Escherichia coli Infections – Discontinued Products 169

Escherichia coli Infections – Product Development Milestones 170

Appendix 181

List of Tables

List of Tables

Number of Products under Development for Escherichia coli Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Tables

Number of Products under Development for Escherichia coli Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Escherichia coli Infections – Pipeline by ABAC Therapeutics SA, H1 2018

Escherichia coli Infections – Pipeline by Adenium Biotech ApS, H1 2018

Escherichia coli Infections – Pipeline by AstraZeneca Plc, H1 2018

Escherichia coli Infections – Pipeline by Atterx Biotherapeutics Inc, H1 2018

Escherichia coli Infections – Pipeline by ContraFect Corp, H1 2018

Escherichia coli Infections – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Escherichia coli Infections – Pipeline by Debiopharm International SA, H1 2018

Escherichia coli Infections – Pipeline by Emergent BioSolutions Inc, H1 2018

Escherichia coli Infections – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Escherichia coli Infections – Pipeline by Hsiri Therapeutics LLC, H1 2018

Escherichia coli Infections – Pipeline by Immuron Ltd, H1 2018

Escherichia coli Infections – Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Escherichia coli Infections – Pipeline by Johnson & Johnson, H1 2018

Escherichia coli Infections – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Escherichia coli Infections – Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Escherichia coli Infections – Pipeline by Melinta Therapeutics Inc, H1 2018

Escherichia coli Infections – Pipeline by Merck & Co Inc, H1 2018

Escherichia coli Infections – Pipeline by Microbiotix Inc, H1 2018

Escherichia coli Infections – Pipeline by Nabriva Therapeutics plc, H1 2018

Escherichia coli Infections – Pipeline by Navigen Inc, H1 2018

Escherichia coli Infections – Pipeline by Northern Antibiotics Oy, H1 2018

Escherichia coli Infections – Pipeline by Nosopharm SAS, H1 2018

Escherichia coli Infections – Pipeline by Novabiotics Ltd, H1 2018

Escherichia coli Infections – Pipeline by Oxford Drug Design Ltd, H1 2018

Escherichia coli Infections – Pipeline by Paratek Pharmaceuticals Inc, H1 2018

Escherichia coli Infections – Pipeline by Phico Therapeutics Ltd, H1 2018

Escherichia coli Infections – Pipeline by Protein Potential LLC, H1 2018

Escherichia coli Infections – Pipeline by PTC Therapeutics Inc, H1 2018

Escherichia coli Infections – Pipeline by Recce Ltd, H1 2018

Escherichia coli Infections – Pipeline by Sealife PHARMA GMBH, H1 2018

Escherichia coli Infections – Pipeline by Syntiron LLC, H1 2018

Escherichia coli Infections – Pipeline by TCM Biotech International Corp, H1 2018

Escherichia coli Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018

Escherichia coli Infections – Pipeline by Venus Medicine Research Center, H1 2018

Escherichia coli Infections – Dormant Projects, H1 2018

Escherichia coli Infections – Dormant Projects, H1 2018 (Contd..1), H1 2018

Escherichia coli Infections – Dormant Projects, H1 2018 (Contd..2), H1 2018

Escherichia coli Infections – Dormant Projects, H1 2018 (Contd..3), H1 2018

Escherichia coli Infections – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Escherichia coli Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Figures

Number of Products under Development for Escherichia coli Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports